NCT06649123Recruiting
Triple Assay of Rectal Mucus in the Diagnosis of Colorectal Cancer
Development of a Multiomics Assay for Use on OriColTM Sampled Rectal Mucus for Detection of Cancer and Significant Polyps in Symptomatic Patients on the Colorectal Urgent Suspected Cancer Pathway
Source: ClinicalTrials.gov · Last updated 4 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Development of a multiomics assay for use on OriColTM sampled rectal mucus for detection of cancer and significant polyps in symptomatic patients on the Colorectal Urgent Suspected Cancer pathway.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 6600 (estimated)
- First submitted
- 16 Oct 2024
- Start date
- 1 Nov 2024
- Primary completion date
- 1 Apr 2026
- Lead sponsor
- Origin Sciences
- Diseases
- Colorectal cancer
- NCT number
- NCT06649123
What you commit to
- Study type: Observational
- Planned participants: 6600
- From 1 Nov 2024 to the primary completion date, 1 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with peri-anal/anal symptoms that may limit DRE and proctoscopy examination and it would be clinically inappropriate to attempt to assess these patients. This may include conditions such as:
- Patients who have undergone radiotherapy.
- An acute or chronic anal fissure
- Perianal haematoma
- Acute thrombosed haemorrhoids
- Post- operative anal stenosis
- The presence of an obstructing anal/low rectal tumour or discomfort as a result of previous pelvic radiotherapy
Other
- Patients who are unable to undergo digital rectal examination (DRE).
- Current pregnancy or suspicion of pregnancy.
Who the study is looking for
- Patients 18 years and over
- Patients referred from primary care to the 'urgent suspected cancer' CRC pathway during the study period.
- Patients who provide voluntary written informed consent to participate in the study.
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shrewsbury & Telford NHS Foundation Trust Coordinator of this site? Confirm its status | Telford | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.